Author:
Kang Therese MJ.,Hardcastle Nicholas,Singh Anurag K.,Slotman Ben J.,Videtic Gregory M.M.,Stephans Kevin L.,Couñago Felipe,Louie Alexander V.,Guckenberger Matthias,Harden Susan V.,Plumridge Nikki M.,Siva Shankar
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference80 articles.
1. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 1.2022). January 21, 2022. Accessed April 1, 2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
2. Videtic GM, Hu C, Singh AK, et al. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927) [published correction appears in Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):638. Timmerman, Robert D [added]].Int J Radiat Oncol Biol Phys. 2015;93(4):757-764. 10.1016/j.ijrobp.2015.07.2260.
3. Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage i peripheral non-small cell lung Cancer;Videtic;Int. J. Radiat. Oncol. Biol. Phys.,2019
4. One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial;Singh;Int. J. Radiat. Oncol. Biol. Phys.,2019
5. Single-fraction vs multifraction stereotactic ablative body radiotherapy for pulmonary oligometastases (SAFRON II): the trans tasman radiation oncology group 13.01 phase 2 Randomized Clinical Trial;Siva;JAMA Oncol.,2021
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献